Kite Flies CAR-T Into Asia With Daiichi Sankyo, Fosun Deals

Now that Kite Pharma Inc.’s first chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel (KTE-C19) is being submitted for US FDA approval, Chairman, President and CEO Arie Belldegrun said it is the right time to think about ways to make the company’s technology available in additional markets, like Japan and China where Kite entered into partnership agreements with Daiichi Sankyo Co. Ltd. and Shanghai Fosun Pharmaceutical Group Co. Ltd., respectively.